|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.810 CAD | +2.18% |
|
-2.43% | -3.44% |
| Capitalization | 91.22M 65.58M 56.53M 52.63M 49M 5.95B 98.15M 605M 239M 2.84B 246M 241M 10.36B | P/E ratio 2026 * |
-36.5x | P/E ratio 2027 * | 7.62x |
|---|---|---|---|---|---|
| Enterprise value | 91.22M 65.58M 56.53M 52.63M 49M 5.95B 98.15M 605M 239M 2.84B 246M 241M 10.36B | EV / Sales 2026 * |
0.65x | EV / Sales 2027 * | 0.55x |
| Free-Float |
69.46% | Yield 2026 * |
-
| Yield 2027 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Medexus Pharmaceuticals Inc.
More recommendations
More press releases
| 1 day | +2.18% | ||
| 1 week | -2.43% | ||
| Current month | -3.44% | ||
| 1 month | +6.04% | ||
| 3 months | +4.07% | ||
| 6 months | -2.43% | ||
| Current year | -3.44% |
| 1 week | 2.73 |  | 3.08 |
| 1 month | 2.59 | | 3.09 |
| Current year | 2.73 | | 3.09 |
| 1 year | 1.96 | | 5.56 |
| 3 years | 1.12 | | 5.56 |
| 5 years | 0.88 | | 9.75 |
| 10 years | 0.88 | | 9.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2018-12-16 | |
Brendon Buschman
DFI | Director of Finance/CFO | - | 2019-05-31 |
Richard Labelle
COO | Chief Operating Officer | - | 2014-02-17 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Mueller
CHM | Chairman | 66 | 2023-04-10 |
Benoit Gravel
BRD | Director/Board Member | - | 2017-09-21 |
| Director/Board Member | - | 2018-10-15 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.18% | -2.43% | -34.65% | +51.89% | 65.58M | |
| +0.53% | -2.37% | +43.09% | +190.27% | 930B | |
| -0.41% | +6.98% | +48.72% | +26.86% | 527B | |
| -0.31% | -2.60% | +24.94% | +40.25% | 379B | |
| +0.93% | +2.38% | +31.46% | +18.47% | 371B | |
| +0.19% | -1.15% | +28.47% | +21.14% | 292B | |
| +0.98% | +1.37% | +29.42% | +35.03% | 276B | |
| -1.93% | -1.54% | +11.14% | -1.47% | 270B | |
| +6.49% | +1.95% | -32.44% | -18.44% | 268B | |
| +0.12% | +1.32% | +21.43% | +22.64% | 178B | |
| Average | +0.88% | +0.39% | +17.16% | +38.67% | 349.1B | |
| Weighted average by Cap. | +0.59% | +0.50% | +29.05% | +65.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 140M 101M 87.01M 81M 75.4M 9.16B 151M 932M 367M 4.37B 378M 371M 15.95B | 165M 119M 102M 95.15M 88.58M 10.76B 177M 1.09B 432M 5.13B 445M 435M 18.74B |
| Net income | -2.37M -1.71M -1.47M -1.37M -1.28M -155M -2.55M -15.76M -6.21M -73.87M -6.4M -6.27M -270M | 12.38M 8.9M 7.67M 7.14M 6.65M 807M 13.32M 82.13M 32.38M 385M 33.36M 32.68M 1.41B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
91
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-16 | 2.810 $ | +2.18% | 14,744 |
| 26-01-15 | 2.750 $ | -3.51% | 50,806 |
| 26-01-14 | 2.850 $ | -1.38% | 32,929 |
| 26-01-13 | 2.890 $ | -2.03% | 33,272 |
| 26-01-12 | 2.950 $ | +2.43% | 46,417 |
Delayed Quote Toronto S.E., January 16, 2026 at 04:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.810CAD
Average target price
6.888CAD
Spread / Average Target
+145.11%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MDP Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition